Expanding access to treatment:

​

Introduction

 

Scientific progress has the greatest impact when patients can access the therapies their physicians recommend. Verax is exploring pricing and patient-access approaches intended to balance affordability, responsible product development, and long-term commercial sustainability.

​

Flex Therapy Pricing™

​

Flex Therapy Pricing™ is a proposed income-based pricing framework for eligible Verax therapies. Under the concept, a patient’s cost would vary according to defined financial criteria rather than relying solely on a single fixed price.

​

The model is intended to reduce affordability barriers while supporting continued research, manufacturing, patient services, and product development. Any future program would need to comply with applicable laws, payer requirements, reimbursement rules, and patient-assistance regulations.

 

Conceptual comparison

 

Traditional fixed-price approach

• Uses a consistent list price.

• Patient access may depend heavily on insurance coverage, reimbursement, and personal financial resources.

• Commercial performance depends on factors including eligibility, coverage, adoption, adherence, competition, and operating costs.

 

Proposed Flex Therapy Pricing™ approach

• Uses defined pricing tiers based on household income or other validated financial criteria.

• Is designed to make treatment accessible to a broader range of eligible patients.

• Would require safeguards, transparent eligibility standards, and legal and regulatory review.

• Must be evaluated for both patient impact and long-term financial sustainability.

 

Verax believes that patient access and sustainable growth should be designed together. Flex Therapy Pricing™ is an early-stage concept, and its final structure, availability, financial impact, and eligibility requirements have not been established.

​

Forward-looking statement

This page contains forward-looking statements about proposed pricing programs, product development, patient access, market acceptance, and potential commercial outcomes. These statements are based on current assumptions and are subject to significant risks and uncertainties. Actual results may differ materially. Verax undertakes no obligation to update forward-looking statements except as required by law.

 

Nothing on this website constitutes an offer to sell or a solicitation of an offer to buy securities.  Any securities offering may be made only through the applicable offering documents and in accordance with federal and state securities laws.